A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors

NCT00880321 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: GSK2118436
DRUG: GSK2118436
DRUG: Midazolam

Sponsor

GlaxoSmithKline